Anakuria Therapeutics

Anakuria Therapeutics - the company is engaged in the development of pharmaceuticals, veterinary and sanitary drugs. It was created by the Navitor Pharmaceuticals group to promote a new class of selective inhibitor analogs that are analogues of rapamycin.

History

2022: Johnson & Johnson купил Anakuria Therapeutics

In early February 2022, it became known about the sale of Anakuria Therapeutics to Janssen Pharmaceuticals (part of the Johnson & Johnson group). The cost of the transaction was not announced.

The Anakuria Therapeutics program, ready for the first phase of the AT-20494 trial, is an orally bioavailable small molecule that selectively inhibits activity, the main modulator of cellular metabolism, which is overactive in many chronic diseases, including autism. AT-20494 belongs to a new class of rapamycins.

Johnson & Johnson acquired Anakuria Therapeutics

We are very pleased that the potential value and substantially differentiated profile of the inhibitor program regulates the rate and ability of the cell to synthesize the protein and other cellular components of Anakuria Therapeutics can be studied with Janssen Therapeutics. With decades of experience in the development, production and commercialization of innovative therapies for patients suffering from a wide range of diseases and conditions, Janssen Therapeutics is well positioned to rapidly advance our program in the clinic. We are also very pleased that the program has come to the family of Johnson & Johnson companies, "said Tom Hughes, President and Chief Executive Officer of Navitor Pharmaceuticals.

Janssen Pharmaceuticals has the opportunity to become the first in its class in the field of autosomal dominant polycystic kidney disease. Under the terms of the agreement, Janssen Pharmaceuticals acquired all outstanding shares of Anakuria Therapeutics, which is now a wholly owned subsidiary of Janssen Pharmaceuticals.^[1]

Notes